457 related articles for article (PubMed ID: 19694996)
21. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light.
Ruane PH; Edrich R; Gampp D; Keil SD; Leonard RL; Goodrich RP
Transfusion; 2004 Jun; 44(6):877-85. PubMed ID: 15157255
[TBL] [Abstract][Full Text] [Related]
22. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling.
Reid S; Johnson L; Woodland N; Marks DC
Transfusion; 2012 Oct; 52(10):2094-103. PubMed ID: 22320126
[TBL] [Abstract][Full Text] [Related]
23. Effects of riboflavin and ultraviolet light treatment on platelet thrombus formation and thrombus stability on collagen.
Terada C; Shiba M; Nagai T; Satake M
Transfusion; 2017 Jul; 57(7):1772-1780. PubMed ID: 28417457
[TBL] [Abstract][Full Text] [Related]
24. Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?
van der Meer PF; Bontekoe IJ; Daal BB; de Korte D
Transfusion; 2015 Aug; 55(8):1900-8. PubMed ID: 25752624
[TBL] [Abstract][Full Text] [Related]
25. Platelet alloimmunization after long-term red cell transfusion in transfusion-dependent thalassemia patients.
Lo SC; Chang JS; Lin SW; Lin DT
Transfusion; 2005 May; 45(5):761-5. PubMed ID: 15847666
[TBL] [Abstract][Full Text] [Related]
26. The detection of platelet antibodies by simultaneous analysis of specific platelet antibodies and the monoclonal antibody-specific immobilization of platelet antigens: an interlaboratory comparison.
Nguyen XD; Goebel M; Schober M; Klüter H; Panzer S
Transfusion; 2010 Jul; 50(7):1429-34. PubMed ID: 20456677
[TBL] [Abstract][Full Text] [Related]
27. Riboflavin and ultraviolet light for pathogen reduction of murine cytomegalovirus in blood products.
Keil SD; Saakadze N; Bowen R; Newman JL; Karatela S; Gordy P; Marschner S; Roback J; Hillyer CD
Transfusion; 2015 Apr; 55(4):858-63. PubMed ID: 25438832
[TBL] [Abstract][Full Text] [Related]
28. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light.
Cardo LJ; Rentas FJ; Ketchum L; Salata J; Harman R; Melvin W; Weina PJ; Mendez J; Reddy H; Goodrich R
Vox Sang; 2006 Feb; 90(2):85-91. PubMed ID: 16430665
[TBL] [Abstract][Full Text] [Related]
29. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology.
Ostrowski SR; Bochsen L; Windeløv NA; Salado-Jimena JA; Reynaerts I; Goodrich RP; Johansson PI
Transfusion; 2011 Feb; 51(2):344-56. PubMed ID: 20723169
[TBL] [Abstract][Full Text] [Related]
30. Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment.
Schubert P; Coupland D; Culibrk B; Goodrich RP; Devine DV
Transfusion; 2013 Dec; 53(12):3164-73. PubMed ID: 23521225
[TBL] [Abstract][Full Text] [Related]
31. Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies.
Picker SM; Schneider V; Oustianskaia L; Gathof BS
Transfusion; 2009 Nov; 49(11):2311-8. PubMed ID: 19624608
[TBL] [Abstract][Full Text] [Related]
32. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.
Slichter SJ; Raife TJ; Davis K; Rheinschmidt M; Buchholz DH; Corash L; Conlan MG
Transfusion; 2006 May; 46(5):731-40. PubMed ID: 16686840
[TBL] [Abstract][Full Text] [Related]
33. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.
Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP
Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498
[TBL] [Abstract][Full Text] [Related]
34. Paired in vitro and in vivo comparison of apheresis platelet concentrates stored in platelet additive solution for 1 versus 7 days.
Shanwell A; Diedrich B; Falker C; Jansson B; Sandgren P; Sundkvist L; Svensson L; Vesterinen M; Gulliksson H
Transfusion; 2006 Jun; 46(6):973-9. PubMed ID: 16734814
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light.
Wagner SJ; Skripchenko A; Myrup A; Awatefe H; Thompson-Montgomery D; Moroff G; Carmichael P; Lin L
Transfusion; 2009 Apr; 49(4):704-10. PubMed ID: 19171001
[TBL] [Abstract][Full Text] [Related]
36. Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions.
Drawz SM; Marschner S; Yañez M; García de Coca A; Feys HB; Deeren D; Coene J
Transfusion; 2015 Jul; 55(7):1745-51. PubMed ID: 25702711
[TBL] [Abstract][Full Text] [Related]
37. Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma.
Smith J; Rock G
Transfusion; 2010 Apr; 50(4):926-31. PubMed ID: 20051060
[TBL] [Abstract][Full Text] [Related]
38. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants.
Asano H; Lee CY; Fox-Talbot K; Koh CM; Erdinc MM; Marschner S; Keil S; Goodrich RP; Baldwin WM
Transplantation; 2007 Nov; 84(9):1174-82. PubMed ID: 17998874
[TBL] [Abstract][Full Text] [Related]
39. Human platelets pathogen reduced with riboflavin and ultraviolet light do not cause acute lung injury in a two-event SCID mouse model.
Chi X; Zhi L; Vostal JG
Transfusion; 2014 Jan; 54(1):74-85. PubMed ID: 23656563
[TBL] [Abstract][Full Text] [Related]
40. Haemostatic function measured by thromboelastography and metabolic activity of platelets treated with riboflavin and UV light.
Ballester-Servera C; Jimenez-Marco T; Morell-Garcia D; Quetglas-Oliver M; Bautista-Gili AM; Girona-Llobera E
Blood Transfus; 2020 Jul; 18(4):280-289. PubMed ID: 32530405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
